adr_usa_0488|MREO|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
adr_usa_0488|MREO|1|Mereo BioPharma Group PLC Total Current Assets (Quarterly) (USD)|Mereo BioPharma Group PLC Cash and Short Term Investments (Quarterly) (USD)|Mereo BioPharma Group PLC Inventories (Quarterly) (USD)|Mereo BioPharma Group PLC Net PP&E (Quarterly) (USD)|Mereo BioPharma Group PLC Goodwill and Intangibles (Quarterly) (USD)|Mereo BioPharma Group PLC Total Liabilities (Quarterly) (USD)|Mereo BioPharma Group PLC Total Current Liabilities (Quarterly) (USD)|Mereo BioPharma Group PLC Total Long Term Liabilities (Quarterly) (USD)|Mereo BioPharma Group PLC Total Deposits (Quarterly) (USD)|Mereo BioPharma Group PLC Book Value (Quarterly) (USD)|Mereo BioPharma Group PLC Retained Earnings (Quarterly) (USD)|Mereo BioPharma Group PLC Treasury Stock (Quarterly) (USD)|Mereo BioPharma Group PLC EV to Revenues|Mereo BioPharma Group PLC EV to Earnings|Mereo BioPharma Group PLC EV to Free Cash Flow|Mereo BioPharma Group PLC EV to Assets (Quarterly)|Mereo BioPharma Group PLC PS Ratio|Mereo BioPharma Group PLC PE Ratio|Mereo BioPharma Group PLC Price to Book Value|Mereo BioPharma Group PLC PEG Ratio|Mereo BioPharma Group PLC Debt to Equity Ratio|Mereo BioPharma Group PLC Dividend Yield|Mereo BioPharma Group PLC Shareholder Yield (TTM)|Mereo BioPharma Group PLC Percent of Shares Outstanding Short|Mereo BioPharma Group PLC Total Receivables (Quarterly) (USD)|Mereo BioPharma Group PLC Total Payables (Quarterly) (USD)|Mereo BioPharma Group PLC Total Capital Stock (Quarterly) (USD)|Mereo BioPharma Group PLC Return on Invested Capital|Mereo BioPharma Group PLC Quality Ratio Score|Mereo BioPharma Group PLC Momentum Score|Mereo BioPharma Group PLC Beta (1Y)|Mereo BioPharma Group PLC Sustainable Growth Rate (TTM)|Mereo BioPharma Group PLC Institutional Investor Ownership Percentage|Mereo BioPharma Group PLC Average Diluted Shares Outstanding (Quarterly)|Mereo BioPharma Group PLC Total Employees (Annual)|Mereo BioPharma Group PLC EPS Diluted (Quarterly) (USD)|Mereo BioPharma Group PLC Shares Outstanding|Mereo BioPharma Group PLC Repurchase of Capital Stock (Quarterly) (USD)|Mereo BioPharma Group PLC Ordinary Shares Number (Quarterly)|Mereo BioPharma Group PLC Payout Ratio|Mereo BioPharma Group PLC Quick Ratio (Quarterly)|Mereo BioPharma Group PLC Normalized Diluted EPS (Quarterly) (USD)|Mereo BioPharma Group PLC Stock Buybacks (Quarterly) (USD)|Mereo BioPharma Group PLC Effective Tax Rate (TTM)|Mereo BioPharma Group PLC Return on Equity|Mereo BioPharma Group PLC Net Income (TTM) (USD)|Mereo BioPharma Group PLC Revenue (TTM) (USD)|Mereo BioPharma Group PLC Dividend Per Share (Quarterly) (USD)|Mereo BioPharma Group PLC Revenue (Quarterly) (USD)|Mereo BioPharma Group PLC Gross Profit (Quarterly) (USD)|Mereo BioPharma Group PLC SG&A Expense (Quarterly) (USD)|Mereo BioPharma Group PLC Pre-Tax Income (Quarterly) (USD)|Mereo BioPharma Group PLC Net Income (Quarterly) (USD)|Mereo BioPharma Group PLC Net Interest Income (Quarterly) (USD)|Mereo BioPharma Group PLC Price (USD)|Mereo BioPharma Group PLC Total Return Price (USD)|Mereo BioPharma Group PLC Enterprise Value (USD)|Mereo BioPharma Group PLC 30-Day Average Daily Volume|Mereo BioPharma Group PLC 1 Year Price Returns (Daily)||
adr_usa_0488|MREO|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
adr_usa_0488|MREO|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
adr_usa_0488|MREO|5|182.555555556|182.555555556|0|182.555555556|182.555555556|182.555555556|182.555555556|182.555555556|0|182.555555556|182.555555556|182.4|0|0|1.44210526316|0|0|0|1.44210526316|0|0|1.44210526316|0|15.2647058824|182.555555556|182.555555556|182.555555556|0|0|30.5|30.6|0|30.4545454545|0|365.25|0|71.4782608696|0|182.555555556|0|0|0|0|182.625|0|182.625|0|0|0|0|0|0|0|0|1.44210526316|1.44210526316|1.44210526316|1.4415954416|1.43307086614||
adr_usa_0488|MREO|6|9|9|0|9|9|9|9|9|0|9|9|5|0|0|380|0|0|0|380|0|0|380|0|34|9|9|9|0|0|4|5|0|11|0|4|0|23|0|9|0|0|0|0|8|0|8|0|0|0|0|0|0|0|0|380|380|380|351|127||
adr_usa_0488|MREO|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
adr_usa_0488|MREO|201512|20.5108|18.1454||0.303|38.2419|6.102|5.8927|0.2094||52.9536|-18.0579||||||||||||||1.5546|2.0578|0.0877||||||||14||12.8682||71.095||||||||||||||||||||||
adr_usa_0488|MREO|201606|100.6374|94.471||0.2547|34.7486|13.293|7.8277|5.4652||122.3477|-26.8095||||||||||||||5.1576|7.8277|0.2598||||||||||12.8682|||||||12.8473||-21.1536|||||||||||||||
adr_usa_0488|MREO|201612|74.6664|65.8206||0.2136|31.7115|9.2237|3.9424|5.2813||97.3677|-49.852||||||||||||||7.127|1.3773|0.2371||||||||20||12.8682|||||||15.5944||-38.1263|||||||||||||||
adr_usa_0488|MREO|201703|||||||||||||||||||||||||||||||||||||14.1208||||||||||||||||||||||||
adr_usa_0488|MREO|201706|82.933|73.6058||0.2189|33.5832|20.4126|15.5211|4.8915||96.3224|-73.1943||||||||||||||6.5451|15.5211|0.2756||||||||||14.1208|||||||17.4548||-46.0449|||||||||||||||
adr_usa_0488|MREO|201709|||||||||||||||||||||||||||||||||||||14.219||||||||||||||||||||||||
adr_usa_0488|MREO|201712|85.3772|71.0089||0.2073|44.6033|45.7476|12.9972|32.7503||84.4402|-107.1875|0|||||||||||||11.3038|4.0867|0.2882||||||||31||14.219||71.095|||||17.3784||-50.3941|||||||||||||||
adr_usa_0488|MREO|201806|64.3758|48.2589||0.1987|42.7389|45.6707|18.4917|27.179||61.6426|-125.7442||||||||||||||14.5144|6.5155|0.279||||||||||14.229||71.1551|||||15.2653||-44.4712|||||||||||||||
adr_usa_0488|MREO|201809|||||||||||||||||||||||||||||||||||||14.2481||||||||||||||||||||||||
adr_usa_0488|MREO|201812|43.7707|34.948||0.1891|41.4067|43.7834|20.527|23.2564||41.5831|-141.1283|0.3896|||||||||||||7.097|5.7989|0.2715||||||||31||14.2481||71.2403|||||14.0878||-42.5007|||||||||||||||
adr_usa_0488|MREO|201903|||||||||||||||-3.7839||||3.002|||0||0.0347|||||||||||||19.2047||||||||||||||||||6.5001|6.5001|117.1467|||4.345|
adr_usa_0488|MREO|201906|61.9502|45.7711||16.6017|57.2262|60.9687|26.6936|34.2751||74.8094|-161.3962|1.6536|||-1.4326||||1.2514|||0||0.0198|12.2907|8.5646|0.3724||||||10.3217||||19.5919||97.9596|||||14.6617||-40.2023|||||||||2.7097|2.7097|44.3532|15620.9667||2.6|3.655
adr_usa_0488|MREO|201909|||||||||||||||-0.8316||||0.7883|||0||0.0132|||||||||10.1649||||||||||||||||||||||3.01|3.01|38.2068|11398.7||3.15|2.3
adr_usa_0488|MREO|201912|39.9055|21.4337||15.1545|58.2894|60.5669|39.1751|21.3917||52.7825|-191.516|1.7111|||-0.4649||||1.2175|||0||1.5811|15.3197|8.3286|0.3855||||||7.9176||50||19.5919||97.9596|||||15.2608||-44.838|||||||||2.15|2.15|21.3578|307216.4333||1.74|1.78
adr_usa_0488|MREO|202003|||||||||||||||-0.5559||||0.493|||0||0.1377||||||1|1.3559||19.6682||||24.9016||||||||||||||||||1.0636|1.0636|32.8478|95553.8|-75.5357|1.23|1.23
adr_usa_0488|MREO|202006|82.077|69.9404||13.8167|39.2358|105.2903|27.5325|77.7578||29.8392|-333.1785|1.6063|||-2.262||||6.947|||0||0.6413|10.4133|6.7564|1.2506|||1|2.1623||87.4354||||67.7428||338.714|||||3.6445||-178.5281|||||||||3.06|3.06|133.6525|537082.1|21.4286|2.79|2.91
adr_usa_0488|MREO|202009|||||||||||||||-3.8244||||5.7892|||0||1.3969||||||4|2.0825||||||||||||||||||||||||2.62|2.62|143.0701|264615.7|-12.0805|2.38|2.37
adr_usa_0488|MREO|202012|40.5115|31.9843||2.1437|43.1308|106.189|11.6726|94.5163||-20.4029|-422.0589|1.7785|||-5.5266||||8.1275|||||8.3528|5.7661|4.5423|1.386|||6|1.9457||||38||67.7906||338.9531|||||1.7202||-206.0109|||||||||3.55|3.55|206.7483|3920436.1333|9.1463|2.69|4.02
adr_usa_0488|MREO|202103|||||||||||||||-9.6292|||||||||7.5932||||||8|0.8842||||||108.2453||||||||||||||||||3.37|3.37|351.5538|3400422.3|222.488|3.57|3.23
adr_usa_0488|MREO|202106|166.5436|152.3687||3.3078|30.7137|88.9026|13.6628|75.2398||111.6625|-411.8853|1.593|||-24.6477|1.0853|||2.4284||0.2223|||10.2437|8.0576|3.0268|2.2615|||8|1.5543||||||108.9021||544.5103||11.7418|||9.0087||-34.5738|||||||||3.17|3.17|322.3276|1558091|3.5948|2.74|2.75
adr_usa_0488|MREO|202109|||||||||||||||-15.2758||||2.4577|||||6.6399||||||3|1.9256||||||||||||||||||||||||2.4|2.4|146.8839|815661.5667|-7.6336|2.14|2.06
adr_usa_0488|MREO|202112|||||||||||||||-4.9174||||1.4727|||||5.4952||||||3|1.803||||||116.9816||||||||||||||||||1.57|1.57|36.8927|1048803.1333|-55.3073|1.16|1.18